Genetic variants associated with cross-disorder and disorder specific risk for psychiatric disorders are enriched at epigenetically active sites in peripheral lymphoid cells

4 Supplementary Material

Mary-Ellen Lynall^{1,2,3,4}, Blagoje Soskic^{5,6}, James Hayhurst⁶, Jeremy Schwartzentruber⁵, Daniel F.
 Levey^{7,8}, Gita A. Pathak^{7,8}, Renato Polimanti^{7,8}, Joel Gelernter^{7,8,9}, Murray B. Stein^{10,11}, Gosia
 Trynka^{5,6}, Menna R. Clatworthy^{3,4}, Ed Bullmore^{1,2}

¹⁰
 ¹University of Cambridge, Department of Psychiatry, Herchel Smith Building of Brain & Mind
 Sciences, Cambridge Biomedical Campus, Cambridge CB2 0SZ, UK

- 14 ²Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK
- ¹⁵
 ³Molecular Immunity Unit, University of Cambridge Department of Medicine, Cambridge, UK
- 18 ⁴Cellular Genetics, Wellcome Sanger Institute, UK
- ⁵Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK
- ⁶Open Targets, Wellcome Genome Campus, Hinxton, UK
- ²³
 ⁷VA Connecticut Healthcare System, West Haven, CT, USA
- ²⁶ ⁸Yale Univ. School of Medicine, Dept Psychiatry, New Haven, CT, USA
- ²⁷
 ⁹Yale Univ. School of Medicine, Depts. Of Genetics and Neuroscience, New Haven, CT, USA
- ³⁰ ¹⁰VA San Diego Healthcare System, San Diego, CA, USA
- ³¹
 ¹¹Department of Psychiatry and School of Public Health, University of California San Diego, La
 ³³ Jolla, CA, USA
- 34

13

17

19

25

29

36 Contents

45

46

47

50

51

54

- Table S1: Genome-wide association study details
- Table S2: Code and data availability
- Table S3: Statistical comparison of original vs. conditional stratified linkage disequilibrium
 score regression (s-LDSC models) by Z-test
- Table S4: s-LDSC results for active regulatory annotations for 88 ROADMAP tissues for all disorders (statistical tables; separate supplementary excel file)
- Figure S1: Enrichment of trans-diagnostic risk at active regulatory elements (active promoters and enhancers) in 88 tissues from the Roadmap epigenomics consortium
 - Figure S2: Cross-disorder psychiatric risk is enriched in brain and lymphoid immune cell active genomic elements
 - Figure S3: Enrichment of genetic risk for multiple psychiatric disorders in immune tissues
- Figure S4: Psychiatric genetic risk enrichment at active lymphoid enhancers/promoters (BLUEPRINT dataset)
 - Figure S5: Psychiatric genetic risk enrichment at activation-dependent T cell enhancers/promoters (Soskic immune stimulation dataset)
- Figure S6: Soskic stimulated immune cell dataset: overlap of H3K27ac peaks implicated by different disorders
 - Figure S7: Soskic stimulated immune cell dataset: pathway enrichment for genes nearest to peaks both specific to T cells and overlapped by risk variants

56 Table S1

Study	Number cases	Number controls	Number of genome-wide independently significant loci	Download link	
Cross-disorder psychiatric risk ¹	162,151	276,846	115	https://pgcdata.med.unc.edu/cross disorde r/pgc cdg2 meta no23andMe oct2019 v2 .txt.daner.txt.gz	
Depression ²	264,984	581,929	122	dbGaP Study Accession: phs001672.v6.p1	
Schizophrenia ³	36,989	113,075	108	https://pgcdata.med.unc.edu/schizophrenia/ ckqny.scz2snpres.gz	
Bipolar disorder	20,352	31,358	16	https://www.med.unc.edu/pgc/download- results/ File = daner_PGC_BIP32b_mds7a_0416a	
Autism ⁵			2	https://pgcdata.med.unc.edu/autism_spectr um_disorders/iPSYCH- PGC_ASD_Nov2017.gz	
ADHD ⁶	19,099	34,194	10	https://pgcdata.med.unc.edu/adhd/adhd_eu r_jun2017.gz	
Body mass index ⁷	806,834	NA	1023	https://zenodo.org/record/1251813#.X_iGV S-I1TZ File = bmi.giant-ukbb.meta- analysis.combined.23May2018.txt	
Alzheimer's disease ⁸	71,880	383,378	25	https://ctg.cncr.nl/documents/p1651/AD_su mstats_Jansenetal_2019sept.txt.gz	
Rheumatoid arthritis ⁹ .	14,361	43,923	48	http://plaza.umin.ac.jp/~yokada/datasource/ files/GWASMetaResults/RA_GWASmeta European_v2.txt.gz	

57

58 **Table S1** Genome-wide association study details. Genetic variants associated trans-diagnostically

59 with risk for 8 psychiatric disorders and cis-diagnostically with risks for each of 5 specific

60 psychiatric / neurodevelopmental disorders, and 3 positive control disorders. Loci associated with

risk were thresholded at $P < 5 \times 10^{-8}$, then distance-based clumping was used to define

62 independently significant loci (see **Methods**).

Table S2 Code and data availability

Resource	Availability		
Code used to perform this	https://github.com/maryellenlynall/psychimmgen20		
analysis and generate the	<u>21</u>		
figures in the paper			
Summary statistics	See Table S1		
Roadmap Epigenomics	http://bx.psu.edu/~yuzhang/Roadmap_ideas/track		
datasets	Db_test.txt		
BLUEPRINT datasets			
Soskic immune stimulation	https://www.ebi.ac.uk/ega/studies/EGAS00001002		
dataset (H3K27ac)	749		
IDEAS annotations	http://bx.psu.edu/~yuzhang/Roadmap_ideas/track		
	Db_test.txt		
1000 genomes called against	http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_coll		
GRCh38	ections/1000_genomes_project/release/20190312		
	_biallelic_SNV_and_INDEL/		
CHEERS code	https://github.com/trynkaLab/CHEERS		
Partitioned LD scores for	Generated in this analysis; available at		
active regulatory elements in	https://doi.org/10.5281/zenodo.5153661		
Roadmap tissues			
GnomAD v2.1.1	https://gnomad.broadinstitute.org		

Table S3 Statistical comparison of original vs. conditional s-LDSC models by *Z*-test (see **Methods**), to accompany **Figure 1B** and **Figure S2A**

inclicacy, to accompany right in and right			
	Original model vs. conditional model including fetal male brain (Fig S2A)	Original model vs. conditional model including fetal female brain (Fig S2A)	
Brain Angular Gyrus	z=1.80; p=0.04	z=2.19; p=0.01	
Brain Anterior Caudate	z=1.74; p=0.04	z=2.20; p=0.01	
Brain Cingulate Gyrus	z=1.75; p=0.04	z=2.19; p=0.01	
Brain Germinal Matrix	z=2.61; p=0.005	z=2.92; p=0.002	
Brain Hippocampus Middle	z=1.50; p=0.07	z=1.99; p=0.02	
Brain Inferior Temporal Lobe	z=1.80; p=0.04	z=2.19; p=0.01	
Brain Dorsolateral Prefrontal Cortex	z=1.94; p=0.03	z=2.31; p=0.01	
Brain Substantia Nigra	z=1.34; p=0.09	z=1.77; p=0.04	
Fetal Brain (female)	z=1.73; p=0.04	NA	
Fetal Brain (male)	NA	z=2.77; p=0.003	
Immune cell subsets for which trans-risk	Original model vs. conditional model		
showed significant enrichment (q < 0.05) in original s-LDSC model	including all 10 significantly enriched brain		
T cytotoxic naive cells (peripheral blood)	z=0.34: n=0.37		
T helper naive cells (peripheral blood) 2	z=0.20; p=0.07		
T cytotoxic memory cells (peripheral blood)	z=0.20, $p=0.42$		
T helper 17 cells (PMA-I stimulated)	z=0.19; p=0.42		
T helper cells (PMA-I stimulated)	z=0.19; p=0.42		
T helper memory cells (peripheral blood) 1	z=0.17; p=0.43		
T regulatory cells (peripheral blood)	z=0.20; p=0.42		
T effector/memory (peripheral blood)	z=0.26; p=0.40		
T helper cells (peripheral blood)	z=0.20; p=0.42		
T helper naive cells (peripheral blood) 1	z=0.28; p=0.39		
T helper memory cells (peripheral blood) 2	z=0.18; p=0.43		
T cells (cord blood)	z=0.23; p=0.41		

72



73 74

75 Figure S1 Enrichment of trans-diagnostic risk at active regulatory elements (active promoters and enhancers) in 88 tissues from the Roadmap epigenomics consortium. P-76 values are shown for the results of stratified linkage disequilibrium score regression (s-LDSC) 77 analysis, taking the union of active elements in a given cell type as the annotation of interest (see 78 79 **Methods**). The *P*-values from s-LDSC were used to test the null hypotheses that risk variants 80 were not co-located with epigenetically activated sites more frequently than expected by chance, at two probability thresholds: P < 0.05 (green); and Benjamini-Hochberg $P_{FDR} < 0.05$ (purple), to 81 correct for multiple tests across N=88 tissues. HUVEC, human umbilical vein endothelial cells; 82 vHMEC, variant human mammary epithelial cells; PFC, prefrontal cortex; HSC, hematopoietic 83 84 stem cell; PMA-I, phorbol-myristate-acetate and ionomycin. A subset of these results is shown in 85 Figure 1A. 86

A Cross-disorder genetic risk: brain tissue enrichment controlling for overlap with active brain tissue elements in male or female fetal brain (benchmarking conditional analysis)



B Cross-disorder genetic risk: conditional analysis for all tissues, controlling for overlap with active brain tissue elements in all brain regions significantly enriched in original LDSC model (Fig 1A)



88 89

90 Figure S2 Cross-disorder psychiatric risk is enriched in brain and lymphoid immune cell

91 active genomic elements (A) Validation of brain-conditioned analysis method: repeat of the

92 analysis in **Figure 1A**, including the active regulatory annotation for fetal male brain as an

93 additional term in the s-LDSC models for other cell types. LHS shows original s-LDSC for brain

regions; RHS shows s-LDSC analysis with the addition of fetal male brain annotation to all models.

- Asterisks indicate those annotations showing significantly decreased enrichment in the conditional compared to the original analysis (two-sample Z-test P < 0.05). (B) Brain-conditioned analysis:
- compared to the original analysis (two-sample Z-test P < 0.05). (B) Brain-conditioned analysis repeat of the analysis in **Figure 1A**, including the active regulatory annotations for all 10
- significantly enriched brain regions as additional terms in the s-LDSC models for all other cell
- 99 types. A subset of these results is shown in **Figure 1B**.

100



 101_{102}

Figure S3 Enrichment of genetic risk for multiple psychiatric disorders in immune tissues
 (A) Enrichment at immune cell enhancers, genic enhancers and active promoters in Roadmap

immune tissues. Enrichment at each annotation was calculated using stratified linkage

105 disequilibrium score regression (s-LDSC). The *P*-values from s-LDSC indicate the significance of 106 the coefficient for the cell type specific annotations. Tile size indicates significance with FDR

107 correction across all 78 annotations tested. Tile fill indicates the *P*-value rank (ranking within each

- annotation across cell types). (B) Correlations between GWAS SNP heritability Z-scores and s-
- 109 LDSC Z-scores for the top two brain and immune annotations for trans-risk. Spearman's
- 110 correlations with heritability z-score are as follows: fetal male brain $\rho = 0.87$, P = 0.005; fetal
- 111 female brain $\rho = 0.87 P = 0.005$; cytotoxic T cells $\rho = 0$, P = 1; helper T cells: $\rho = 0.03$, P = 0.9.
- 112



114 Figure S4 Psychiatric genetic risk enrichment at active lymphoid enhancers/promoters

- (BLUEPRINT dataset) (A) Bar plots show enrichment of genetic risk for each condition at active
- 116 promoters/enhancers (H3K27ac marks) in unstimulated sorted immune cells. CHEERS was used 117 to detect enrichment of risk loci at cell-type specific H3K27ac peaks by quantifying (for each cell
- 118 type) the mean cell type specificity score (for that cell type) of peaks overlapping genetic risk
- variants (see **Methods**). The dotted black line marks the nominal significance threshold, P < 0.05;
- the solid black line marks the Bonferroni-corrected significance threshold, $P_{FDR} < 0.05$. Note
- 121 differing x-axis scales. (B) Upset plot for all Soskic immune stimulation H3K27ac immune peaks
- overlapped by risk variants for each disorder, showing counts (vertical bars) of shared peaks,
- 123 compared to total peak number implicated by each disorder (horizontal bars).
- 124
- 125





Figure S5 Psychiatric genetic risk enrichment at activation-dependent T cell enhancers/promoters (Soskic immune stimulation dataset). Bar plots show enrichment of genetic risk for each condition at active promoters/enhancers (H3K27ac marks) in unstimulated and *ex vivo* stimulated immune cells. Stimulated cells are sorted macrophages, naïve CD4⁺

- 131 (helper) T cells and memory CD4⁺ T cells, assayed at both early and late timepoints (see legend).
- 132 CHEERS was used to detect enrichment of risk loci at cell-type specific H3K27ac peaks by
- quantifying, for each cell type, the mean cell type specificity score (for that cell type) of peaks
 overlapping genetic risk variants (see **Methods**). P-values are reported from a discrete uniform
- overlapping genetic risk variants (see Methods). P-values are reported from a discrete uniform
 distribution. The dotted black line marks raw *P* < 0.05; the solid black line marks Bonferroni-
- 136 corrected $P_{FDR} < 0.05$. Note differing x-axis scales.
- 137



139 Figure S6 Soskic stimulated immune cell dataset: overlap of H3K27ac peaks implicated by

different disorders (A) Heatmap shows the subset of peaks with specificity for late-activated 140 naïve and/or memory CD4⁺ T cells which are also overlapped by risk variants for either trans-risk, 141 schizophrenia, or major depressive disorder. Each row corresponds to a H3K27ac peak 142 overlapping a risk variant; each column corresponds to a different cytokine-induced cell state (see 143 legend), ordered as in Figure 4A. Blue fill shade represents how specific each peak is to each cell 144 state (specificity rank of the peak normalized to the mean specificity rank of all peaks). Row 145 annotations indicate peaks which overlap (dark red) or do not overlap (grey) risk variants for the 146 disorder indicated. Of the late-activation T cell specific peaks, only 1 (starred *) is overlapped by 147 both schizophrenia and depression risk variants. (B) Upset plot for all Soskic dataset H3K27ac 148 immune peaks overlapped by risk variants for each disorder, showing counts (vertical bars) of 149 shared peak overlaps, compared to total number of peaks implicated by each disorder (horizontal 150 bars). 151 152



155

Figure S7 Soskic stimulated immune cell dataset: pathway enrichment for genes nearest to 156 peaks both specific to T cells and overlapped by risk variants. Results are shown for those 157 disorders which showed enrichment in T cell subset. Peaks which both overlapped a disease-158 specific risk variant and were highly specific (specificity rank > 0.9) to any of the T cell subsets in 159 the Soskic immune stimulation dataset were selected, and nearest genes identified (see 160 Methods). For these genes, over-representation analysis was used to detect pathway enrichment 161 in Reactome and GO Biological Process pathways. Only pathways with $P_{FDR} < 0.05$ are shown, 162 163 with a maximum of 10 pathways shown per condition. Fill colour indicates gene ratio (number of

test genes in the pathway / total number of test genes).

165 Supplementary references

166

- Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic Relationships,
 Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell* **179**, 1469 1482 e1411, doi:10.1016/j.cell.2019.11.020 (2019).
- Levey, D. F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and metaanalysis in >1.2 million individuals highlight new therapeutic directions. *Nat Neurosci*, doi:10.1038/s41593-021-00860-2 (2021).
- 173 3 Ripke, S. *et al.* Genome-wide association analysis identifies 13 new risk loci for 174 schizophrenia. *Nat Genet* **45**, 1150-1159, doi:10.1038/ng.2742 (2013).
- 175 4 Stahl, E. A. *et al.* Genome-wide association study identifies 30 loci associated with bipolar 176 disorder. *Nat Genet* **51**, 793-803, doi:10.1038/s41588-019-0397-8 (2019).
- 1775Grove, J. et al. Identification of common genetic risk variants for autism spectrum disorder.178Nat Genet **51**, 431-444, doi:10.1038/s41588-019-0344-8 (2019).
- 179 6 Demontis, D. *et al.* Discovery of the first genome-wide significant risk loci for attention
- deficit/hyperactivity disorder. *Nat Genet* 51, 63-75, doi:10.1038/s41588-018-0269-7 (2019).
 Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* 28, 166-174,
- 183 doi:10.1093/hmg/ddy327 (2019).
- 184 8 Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways
 185 influencing Alzheimer's disease risk. *Nat Genet* **51**, 404-413, doi:10.1038/s41588-018 186 0311-9 (2019).
- 187 9 Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and drug discovery.
 188 Nature 506, 376-381, doi:10.1038/nature12873 (2014).